Top Startup and Tech Funding News Roundup – Week Ending November 7, 2025

It’s Friday, November 7, 2025, and we’re back with the Top Startup and Tech Funding News Roundup – Week of November 3, 2025. This week, investors poured billions into AI, robotics, biotech, crypto, climate tech, and frontier hardware, backing everything from gene therapies and brain-computer interfaces to AI-native revenue platforms and physical-world fintech.

The biggest checks went to late-stage giants like Metropolis, Ripple, Armis, Beacon Software, and Synchron, while ambitious newcomers such as General Intuition, Inception, and Braveheart Bio raised unusually large early-stage rounds to chase big technical and clinical bets.

Funding Highlights

• Metropolis raised $500M Series D at a $5B valuation to scale its AI-powered parking and real-world payments platform.

• Ripple landed $500M at a $40B valuation to build out its crypto banking ambitions.

• Armis secured $435M in a pre-IPO round at a $6.1B valuation as it targets $1B ARR in cybersecurity.

• Synchron closed a $200M Series D to commercialize its minimally invasive brain-computer interface.

• Braveheart Bio launched with a $185M Series A to take on heart disease.

Here’s the full breakdown. Until next week, have a great weekend.

AAVantgarde Bio Closes $141M in Series B Funding for Gene Therapy Innovation

Italy-based biotech AAVantgarde Bio has closed a $141 million Series B funding round to advance its next-generation gene therapy platform aimed at treating inherited retinal diseases. The company’s proprietary AAV-based technology enables the delivery of large or multiple genes that cannot fit within traditional viral vectors.

The capital will fund ongoing clinical trials and support the expansion of its ophthalmology and neurology pipeline. With the new investment, AAVantgarde Bio aims to become a global leader in gene therapy development, targeting conditions previously considered untreatable.

Funding Details:

• Startup: AAVantgarde Bio

• Investors: RTW Investments (lead), Forbion, and Sofinnova Partners

• Amount Raised: $141 million

• Total Raised: $190 million

• Funding Stage: Series B

• Funding Date: November 3, 2025

Hippocratic AI Raises $126M in Series C Funding at $3.5B Valuation

Hippocratic AI, a health technology startup building patient-facing AI agents, has secured $126 million in Series C funding to expand its suite of clinical and administrative tools for hospitals and insurers. The company’s AI models are designed to safely handle sensitive patient interactions, offering a scalable alternative to traditional telehealth triage systems.

This round pushes Hippocratic AI’s valuation to $3.5 billion, reflecting investor confidence in AI’s role in healthcare. The company plans to use the fresh capital to accelerate clinical trials, pursue regulatory approvals, and expand into new markets across North America and Europe.

Founded by CEO Munjal Shah, along with a group of physicians, hospital administrators, and AI researchers from institutions such as El Camino Health, Johns Hopkins, Stanford, Microsoft, Google, and NVIDIA, Hippocratic AI is developing generative AI agents for healthcare. The startup has already partnered with more than 50 healthcare organizations, including Cleveland Clinic, Northwestern Medicine, Ochsner Health, Moffitt Cancer Center, and University Hospitals.

Funding Details:

• Startup: Hippocratic AI

• Investors: General Catalyst (lead), Andreessen Horowitz, Premji Invest, and SV Angel

• Amount Raised: $126 million

• Total Raised: Over $230 million

• Funding Stage: Series C

• Funding Date: November 3, 2025

General Intuition Launches with $133.7M in Seed Funding to Build Spatial-Temporal AI Agents

General Intuition, a freshly-launched research startup spun out of gaming platform Medal, has raised a $133.7 million seed round to pioneer AI agents with spatial-temporal reasoning. The company will train these agents on massive video-game datasets and aims to apply the tech to domains such as rescue drones and real-world robotics.

The size of this seed is unusual and typically reserved for later stages. It underscores how investors are placing big bets on next-generation AI architectures beyond text. The funding was raised from heavyweight backers, including Khosla Ventures, General Catalyst, and Raine, signaling belief in the firm’s ambition to push toward artificial general intelligence in the long term.

Funding Details:

• Startup: General Intuition

• Investors: Khosla Ventures (lead), General Catalyst, Raine

• Amount Raised: $133.7 million

• Total Raised: $133.7 million (launch)

• Funding Stage: Seed

• Funding Date: November 3, 2025

Beacon Software Raises $250 Million in Series B Funding to Modernize Vertical Software with AI

Beacon Software, a platform that acquires and transforms niche vertical software companies with artificial intelligence, has closed a massive $250 million Series B round to accelerate its “AI-led roll-up” strategy. The company’s model focuses on revitalizing software products serving underrepresented industries, from youth sports leagues to manufacturing, by embedding AI capabilities and engineering support rather than cost-cutting.

The round values Beacon at approximately $1 billion and brings its total funding to about $335 million. The fresh capital will fund more acquisitions, expand its AI integration team, and enhance its shared infrastructure across portfolio companies. Beacon’s founders describe their approach as “anti-private-equity,” focusing on long-term product innovation and sustainability instead of financial arbitrage.

Founded by former Instacart President Nilam Ganenthiran and ex-Sequoia Capital partner Divya Gupta, Beacon targets the kind of self-funded software businesses that rarely attract venture money, such as those serving youth sports leagues, campgrounds, manufacturers, and even unions. These businesses typically generate under $20 million in annual recurring revenue but are solidly profitable.

Funding Details:

• Startup: Beacon Software

• Investors: General Catalyst (lead), Lightspeed Venture Partners, D1 Capital

• Amount Raised: $250 million

• Total Raised: ~$335 million

• Funding Stage: Series B

• Funding Date: November 4, 2025

The Every Company Raises $55M Series D to Scale Precision-Fermented Egg Proteins

The Every Company, a San Francisco-based food-tech startup, has secured $55 million in a Series D funding round to accelerate commercial production of its precision-fermented egg-protein ingredients. The company’s technologies replace conventional chicken-egg proteins in applications ranging from baked goods and pasta to beverages and coffee syrups. It is positioning itself to disrupt the large, inflation-pressured egg market.

With products already featured at national retailer Walmart, The Every Company has demonstrated proof-of-scale in real-world applications. The new funding will enable expansion of manufacturing capacity, broaden the company’s ingredient footprint across food-service and consumer goods, and move the business toward profitability in a category that is rapidly gaining investor attention.

Funding Details:

• Startup: The Every Company

• Investors: McWin Capital Partners (lead via McWin Food Tech Fund), Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, SOSV

• Amount Raised: $55 million

• Total Raised: $288 million (prior total)

• Funding Stage: Series D

• Funding Date: November 4, 2025

Hypersonix Launch Systems Secures $46M in Series A Funding to Advance Hydrogen-Powered Hypersonic Aircraft

Australia’s Hypersonix Launch Systems, which is developing reusable, hydrogen-powered hypersonic aircraft and scramjet engines, announced a funding round of approximately $46 million in Series A financing. The raise supports the next phase of its DART AE and VISR demonstrators, aligning with NASA-backed and national-security-oriented hypersonic development.

The startup, founded in 2019 by a former NASA scientist, is pitching itself as a pioneer in hydrogen-fuelled supersonic flight, potentially reaching speeds beyond Mach 10 with reusable aircraft. The fresh capital will accelerate engineering, testing, and manufacturing at its Brisbane facility, as aerospace investment flows into the next frontier of vehicle design.

Funding Details:

• Startup: Hypersonix Launch Systems

• Investors: High Tor Capital (lead, UK national-security investor), Queensland Investment Corporation, Saab, others

• Amount Raised: ~$46 million

• Total Raised: Not publicly disclosed

• Funding Stage: Series A

• Funding Date: November 4, 2025

Ripple Lands $500M in Funding at $40B Valuation to Build Out Crypto Banking Empire

Blockchain pioneer Ripple has landed a massive $500 million funding round that values the company at $40 billion, marking one of the year’s largest crypto financings. The raise was led by a cadre of Wall Street heavyweights, including Fortress Investment Group and Citadel Securities, with participation from major crypto investors like Pantera Capital, Galaxy Digital, Brevan Howard, and Marshall Wace. This strategic late-stage investment provides Ripple with a war chest to expand beyond its origins in cross-border payments and transform into a full-service crypto banking platform. It also signals growing institutional confidence in blockchain infrastructure at a time of more favorable regulatory tailwinds for crypto ventures.

Founded in 2012 and known for the XRP cryptocurrency, Ripple has spent recent years diversifying its offerings through acquisitions and new products. The company now delivers services ranging from stablecoin issuance and crypto custody to prime brokerage and treasury management, effectively positioning itself as an institutional crypto bank. CEO Brad Garlinghouse noted that 2025 has been a record year as Ripple evolved into a crypto-native financial services provider. With six acquisitions completed in the past two years and this half-billion in fresh capital, Ripple is poised to accelerate its push into mainstream finance. The funding will bolster Ripple’s ability to compete with traditional financial institutions by providing blockchain-based alternatives for payments and banking, solidifying its status as one of the most valuable private companies in crypto.

Funding Details:

• Startup: Ripple

• Investors: Fortress Investment Group, Citadel Securities, Pantera Capital, Galaxy Digital, Brevan Howard, Marshall Wace

• Amount Raised: $500 million

• Total Raised: Not disclosed

• Funding Stage: Strategic investment round (late-stage)

• Funding Date: November 5, 2025

Armis Raises $435M in Pre-IPO Funding Round at $6.1B Valuation for Cybersecurity Growth

Armis, a San Francisco-based cybersecurity startup specializing in asset protection for enterprises, has secured a hefty $435 million pre-IPO funding round to fuel its expansion and pave the way for an expected IPO in 2026. The nine-year-old company, known for safeguarding critical infrastructure and IoT devices, saw its valuation jump to $6.1 billion with this round. The investment was led by Goldman Sachs’ Growth Equity arm, with participation from Alphabet’s CapitalG and Evolution Equity Partners. Armis reportedly turned down multiple acquisition offers, including a $5 billion bid from Thoma Bravo, in favor of this funding, underscoring its ambitions to remain independent and go public on its own terms.

Armis plans to use the fresh capital to accelerate product innovation and global go-to-market efforts as it marches toward $1 billion in annual recurring revenue. The company has already surpassed $300 million ARR this year and serves over 40% of the Fortune 100 among its customers. By “behaving like a public company” and hitting aggressive growth targets, Armis aims to become a multigenerational cybersecurity leader focused on unified cyber exposure management. The sizable pre-IPO round, coming just a year after a $200 million raise at a $4.2 billion valuation, signifies strong investor confidence in Armis’ trajectory as it prepares for a potential late-2026 IPO.

Funding Details:

• Startup: Armis

• Investors: Goldman Sachs Alternatives (lead), CapitalG, Evolution Equity Partners (among others)

• Amount Raised: $435 million

• Total Raised: Not disclosed (estimated over $1 billion)

• Funding Stage: Pre-IPO round

• Funding Date: November 5, 2025

Braveheart Bio Launches with $185M in Series A Funding to Tackle Heart Disease

Newly formed biotech Braveheart Bio has burst onto the scene with an impressive $185 million Series A financing to develop what it hopes will be a breakthrough treatment for a serious heart disease. The Boston-based startup formally launched on November 5 with one of the largest first-round biotech fundings in recent memory. Its focus is a drug candidate (BHB-1893) for hypertrophic cardiomyopathy, a condition where the heart muscle thickens abnormally, which Braveheart licensed from China’s Hengrui Pharmaceuticals in a deal earlier this year. Hengrui had already advanced the drug into Phase 2 and Phase 3 trials in China, and Braveheart will use the new capital to kick off global late-stage trials in 2026 to prove the therapy can be best-in-class against existing treatments. The sizable Series A indicates high conviction that Braveheart’s approach could challenge Bristol Myers Squibb’s Camzyos, currently the only approved HCM drug, by delivering better efficacy or safety for patients.

Braveheart Bio is led by CEO Travis Murdoch, the former head of an immunology startup acquired by Biogen, and its chairman is Biogen CEO Chris Viehbacher, bringing seasoned leadership to the young company. The startup’s investor syndicate features about half a dozen top-tier life science funds, among them Andreessen Horowitz (a16z), Forbion, and OrbiMed. With this strong backing, Braveheart intends to move quickly. The funding will support aggressive clinical development of BHB-1893 and build out the company’s operations. The broader strategy, as evidenced by Braveheart’s formation, is to scout promising drug assets globally and develop them in the West. Thanks to one of the year’s largest Series A rounds, Braveheart now has the resources to potentially bring a much-needed new therapy to HCM patients worldwide if its program succeeds in pivotal trials.

Funding Details:

• Startup: Braveheart Bio

• Investors: Andreessen Horowitz, Forbion, OrbiMed, and others

• Amount Raised: $185 million

• Total Raised: $185 million

• Funding Stage: Series A

• Funding Date: November 5, 2025

Metropolis Raises $500M in Series D Funding for AI-Powered Parking Platform

Metropolis, a Los Angeles-based startup transforming parking with computer vision and AI, has secured a massive $500 million Series D funding round at a valuation of about $5 billion. The raise is part of a larger $1.6 billion financing package that includes debt, as the company accelerates its expansion beyond parking lots into broader real-world transaction infrastructure. Metropolis’s checkout-free platform uses cameras and machine learning to let drivers park and leave without stopping for payment, automatically charging them and emailing receipts. This funding, one of the year’s largest, will fuel growth initiatives, including the rollout of its technology to new sectors like retail and hospitality, following Metropolis’s $1.5 billion acquisition of parking operator SP+ earlier this year, which swelled its workforce to over 23,000 employees.

Founded by CEO Alex Israel, Metropolis aims to eliminate friction in daily mobility and commerce. Its AI-powered system tracks vehicles and handles payments seamlessly, positioning the company at the forefront of “physical world” fintech. The Series D round was led by a fund managed by LionTree, with participation from affiliates of BDT & MSD Partners, signaling strong investor confidence in Metropolis’s vision. To date, the company has raised roughly $3.5 billion, including debt, to build out its platform. With the new capital, Metropolis plans to scale to more cities, pursue strategic acquisitions, and continue innovating its platform so any venue, from garages to gas stations, can offer a smooth, automated experience.

Funding Details:

• Startup: Metropolis

• Investors: LionTree (lead, via managed fund), BDT & MSD Partners (affiliates), among others

• Amount Raised: $500 million

• Total Raised: approx. $3.5 billion (including debt financing)

• Funding Stage: Series D

• Funding Date: November 6, 2025

Synchron Secures $200M in Series D Funding to Advance Brain-Computer Interfaces

Synchron, a pioneer in minimally invasive brain-computer interface (BCI) technology, announced a $200 million Series D financing to accelerate the commercialization of its neural implant platform. The New York-based medtech startup is known for developing the Stentrode, the first endovascular BCI that can be implanted without open-brain surgery. Placed via a catheter into a blood vessel in the brain, the Stentrode has enabled patients with paralysis to control digital devices by thought, translating neural signals into action wirelessly. With ten patients already implanted across U.S. and Australian clinical trials, Synchron’s device has demonstrated the potential to restore communication and independence for people with severe paralysis. The new funding will help Synchron ramp up pivotal clinical trials and prepare for a commercial launch of the Stentrode system, bringing this breakthrough closer to everyday healthcare use.

This oversubscribed round was led by Double Point Ventures, with participation from a roster of top investors, old and new. Existing backers like ARCH Venture Partners, Khosla Ventures, and Bezos Expeditions joined in, alongside new investors including the Australian government’s National Reconstruction Fund, Qatar Investment Authority, and T. Rx Capital. The infusion brings Synchron’s total funding to about $345 million to date. Founder and CEO Dr. Tom Oxley says the capital will also fuel development of a next-generation, higher-bandwidth BCI and the growth of Synchron’s “NeuroAI” data science team to decode brain signals in real time. As competition in the BCI field heats up, including efforts by Elon Musk’s Neuralink, Synchron’s less invasive approach and early clinical head start have positioned it as a leader. With fresh funding, the company is poised to scale up operations, hire engineering and neuroscience talent, and ultimately get its device FDA-approved for widespread use, a milestone that could transform life for patients with neurological injuries or disease.

Funding Details:

• Startup: Synchron

• Investors: Double Point Ventures (lead), ARCH Venture Partners, Khosla Ventures, Bezos Expeditions, National Reconstruction Fund (Australia), Qatar Investment Authority, T.Rx Capital, and others

• Amount Raised: $200 million

• Total Raised: $345 million

• Funding Stage: Series D

• Funding Date: November 6, 2025

Inception Lands $50M Seed Funding to Pioneer Diffusion Models for AI

Inception, an AI research startup aiming to revolutionize how machines generate code and text, has emerged from stealth with a $50 million seed funding round. Founded by Stanford professor Stefano Ermon and a team of AI scientists, the company is developing diffusion-based AI models that depart from the typical ChatGPT-like approach to language. Diffusion models generate content by iteratively refining the entire output, an approach proven in image AI like Stable Diffusion, rather than predicting words sequentially. Inception believes this technique can dramatically improve speed and efficiency for large language models when handling tasks like code generation. The seed round, one of the largest early-stage AI investments this year, was led by Menlo Ventures and attracted a who’s who of tech investors, including Mayfield Fund, Innovation Endeavors, Microsoft’s M12 venture arm, Snowflake Ventures, Databricks Ventures, and Nvidia’s NVentures, as well as notable angel backers like Andrew Ng and Andrej Karpathy.

With the new funding, Inception is quickly scaling up its research and engineering efforts. The startup has already unveiled an early product called Mercury, a diffusion model tailored for software development that can assist with writing and debugging code. Mercury is reportedly being piloted in developer tools such as ProxyAI and Buildglare, showcasing the model’s ability to integrate into real-world programming workflows. Inception’s approach promises significant gains. By generating code via diffusion, its models aim to reduce the computational cost and latency associated with today’s AI coding assistants. The seed capital will enable Inception to hire top-tier AI researchers and double down on R&D to push the boundaries of diffusion models. While still at an early stage, the company’s vision is to unlock AI that can handle large-scale text and code tasks more holistically and efficiently.

Funding Details:

• Startup: Inception

• Investors: Menlo Ventures (lead), Mayfield Fund, Innovation Endeavors, Microsoft M12, Snowflake Ventures, Databricks Ventures, NVentures, with angel funding from Andrew Ng, Andrej Karpathy, and others

• Amount Raised: $50 million

• Total Raised: $50 million (seed round)

• Funding Stage: Seed

• Funding Date: November 6, 2025

Tech Funding Summary Table – Week of November 3, 2025